Indivumed, Definiens Partner
News Jul 20, 2016
Definiens and Indivumed have announced a strategic partnership to offer a unique combination of tissue-based biomarker validation and assay development with Definiens Cognition Network Technology® for image analysis and data mining.
This partnership will allow researchers and clinicians in oncology to benefit from a joint offering of Indivumed’s leading Cancer Database, Biobank and analytical laboratory services for tissue analysis together with Definiens’ leading proprietary Cognition Network Technology® and the Tissue Phenomics® approach to oncology and diagnostics.
Indivumed specializes in stringent and highly standardized tissue collection processes that preserve biomolecules such as RNA and protein, allowing more accurate assessment of tissue patterns and more rigorous comparisons across samples. “Customers of either company can now benefit from this partnership and our comprehensive approach for image analysis and tissue-based research and development in oncology,” said Hartmut Juhl, Founder and Chief Executive Officer, Indivumed.
“In the quest to use tissue biomarkers to create diagnostic tests for cancer patients, there is no question that the quality of tissue combined with advanced image analysis and tissue mining is extremely important,” commented Ralf Huss, Chief Medical Officer, Definiens.
“This partnership allows researchers and clinicians to benefit from the expertise of both our companies and advance personalized medicine for the treatment of patients. It will be great to see this partnership benefit not only researchers and clinicians, but also ultimately cancer patients.”
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE